The FDA rejected AstraZeneca's subcutaneous Saphnelo application, delaying U.S. approval until 2026, despite positive clinical trial results. The subcutaneous formulation allows self-administration, ...
AstraZeneca AZN and its Japan-based partner Daiichi Sankyo announced that the FDA has accepted and granted priority review to their supplemental biologics license application (sBLA) seeking approval ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results